Hanmi stellt auf der Society for Immunotherapy of Cancer (SITC) in den USA ein Poster zu BH3120 vor, das sich in der Entwicklung befindet. Phase-1-Studie verläuft reibungslos, keine dosislimitierende Toxizität beobachtet Phase-1-Studie zur Evaluierung der Kombination von BH3120 und…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.